Understand the source comparison
GHK-Cu vs TB-500 vs Growth Factor Mimetics—Mechanism and Application Context
GHK-Cu (Copper Peptide) TGF- downregulation, VEGF upregulation, collagen synthesis in dermal papilla 340 Da Topical (penetrates intact skin) 18% hair count increase at 12 weeks (Journal of Drugs in Dermatology, 2015) Strongest clinical evidence for topical us
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- GHK-Cu (Copper Peptide)
- TGF-β downregulation, VEGF upregulation, collagen synthesis in dermal papilla
- 340 Da
- Topical (penetrates intact skin)
- 18% hair count increase at 12 weeks (Journal of Drugs in Dermatology, 2015)
- Strongest clinical evidence for topical use—requires consistent twice-daily application at 1–5 µM
- TB-500 (Thymosin Beta-4)
- Actin sequestration, anagen extension, basement membrane protein upregulation
- 4963 Da
- Requires microneedling or systemic injection
- Mouse models show 14-day anagen extension—no published human trials
- Mechanistically sound but delivery route is the constraint—topical formulations unlikely effective
- Growth Factor Mimetics (e.g., Cartalax)
- Telomerase modulation, stem cell senescence reduction
- 300–500 Da
- Topical or systemic
- Limited to animal models—no human hair-specific data
- Theoretical benefit through stem cell preservation—evidence base too thin for clinical recommendation
- GHK-Cu is the most practical choice for topical application—it penetrates skin, has published human data, and targets a known pathological pathway (elevated TGF-β) in androgenetic alopecia. The limitation: effects plateau after 12–16 weeks, suggesting the compound extends existing anagen follicles but doesn't reverse miniaturisation. Combining GHK-Cu with minoxidil (a potassium channel opener) or microneedling produces additive effects because the mechanisms don't overlap.
- TB-500 offers stronger anagen extension in preclinical models but faces a delivery problem—topical application is ineffective, and systemic injection raises cost and compliance barriers. Patients using TB-500 for other indications (injury recovery, inflammation) report anecdotal hair quality improvements, but no controlled trials exist. If pursuing TB-500 for hair loss, microneedling at 1.5 mm depth immediately before application is the minimum requirement for dermal penetration.
- Growth factor mimetics remain experimental. Cartalax and similar compounds show promise in tissue regeneration studies, but extrapolating stem cell effects to hair follicles requires follicle organ culture validation that doesn't yet exist. These peptides are better suited to research contexts than clinical application until human hair-specific data emerges.